WallStSmart

Bausch + Lomb Corp (BLCO)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Bausch + Lomb Corp generates 62% more annual revenue ($5.21B vs $3.22B). WST leads profitability with a 16.9% profit margin vs -4.2%. BLCO appears more attractively valued with a PEG of 0.89. WST earns a higher WallStSmart Score of 65/100 (C+).

BLCO

Hold

44

out of 100

Grade: D

Growth: 5.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: 0.91

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BLCOSignificantly Overvalued (-78.0%)

Margin of Safety

-78.0%

Fair Value

$9.57

Current Price

$15.26

$5.69 premium

UndervaluedFair: $9.57Overvalued
WSTSignificantly Overvalued (-55.4%)

Margin of Safety

-55.4%

Fair Value

$158.40

Current Price

$329.71

$171.31 premium

UndervaluedFair: $158.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLCO2 strengths · Avg: 9.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

PEG RatioValuation
0.898/10

Growing faster than its price suggests

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

BLCO4 concerns · Avg: 2.5/10
Operating MarginProfitability
4.7%3/10

Operating margin of 4.7%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-3.4%2/10

ROE of -3.4% — below average capital efficiency

EPS GrowthGrowth
-88.6%2/10

Earnings declined 88.6%

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
44.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : BLCO

The strongest argument for BLCO centers on Price/Book, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : BLCO

The primary concerns for BLCO are Operating Margin, Piotroski F-Score, Return on Equity.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.

Key Dynamics to Monitor

BLCO profiles as a turnaround stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

WST scores higher overall (65/100 vs 44/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bausch + Lomb Corp

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Bausch Lomb Corporation is an eye health company in Canada and internationally. The company is headquartered in Vaughan, Canada.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?